Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Diabetic nephropathy

Renoprotective effects of GLP1R agonists and SGLT2 inhibitors

New data from the LEADER trial show that the glucagon-like peptide 1 receptor agonist liraglutide protects against diabetic nephropathy in patients with type 2 diabetes mellitus. The renoprotective efficacy of liraglutide is not, however, as great as that reported for the sodium-glucose cotransporter 2 inhibitor emplagiflozin in the EMPA-REG OUTCOME trial.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Muskiet, M. H. et al. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Nat. Rev. Nephrol. 13, 605–628 (2017).

    Article  CAS  Google Scholar 

  2. DeFronzo, R. A. et al. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat. Rev. Nephrol. 13, 11–26 (2017).

    Article  CAS  Google Scholar 

  3. Mann, J. F. et al. Liraglutide and renal outcomes in type 2 diabetes. N. Engl. J. Med. 377, 839–848 (2017).

    Article  CAS  Google Scholar 

  4. Wanner, C. et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N. Engl. J. Med. 375, 323–334 (2016).

    Article  CAS  Google Scholar 

  5. Marso, S. P. et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375, 311–322 (2016).

    Article  CAS  Google Scholar 

  6. Zinman, B. et al. Empagliflozin and cerebrovascular events in patients with type 2 diabetes mellitus at high cardiovascular risk. Stroke 48, 1218–1225 (2017).

    Article  CAS  Google Scholar 

  7. Lewis, E. J. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345, 12 (2001).

    Google Scholar 

  8. Brenner, B. M. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 12 (2001).

    Article  Google Scholar 

  9. Hocher, B. Adenosine A1 receptor antagonists in clinical research and development. Kidney Int. 78, 438–445 (2010).

    Article  CAS  Google Scholar 

  10. Tsuprykov, O. et al. The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy. Kidney Int. 89, 1049–1061 (2016).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Berthold Hocher.

Ethics declarations

Competing interests

B.H. is a consultant for Boehringer Ingelheim on the development of dipeptidyl peptidase 4 (DPP4) inhibitors and has received research funding from this company for investigation of the renal effects of the DPP4 inhibitor linagliptin. O.T. declares no competing interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hocher, B., Tsuprykov, O. Renoprotective effects of GLP1R agonists and SGLT2 inhibitors. Nat Rev Nephrol 13, 728–730 (2017). https://doi.org/10.1038/nrneph.2017.140

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneph.2017.140

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing